Rituximab® and high dose methylprednisolone (HDMP) as a first line treatment for patients with chronic lymphocytic leukemia

被引：0
|
作者：
Castro, JE
Bole, JE
Prada, CE
Loria, O
Kipps, TJ
机构：
[1] Univ Calif San Diego, John & Rebecca Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Chron Lymphocyt Leukemia Res Consortium, San Diego, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2969
引用
收藏
页码：833A / 833A
页数：1
相关论文
共 50 条
  • [1] Rituximab® and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
    Castro, JE
    Bole, J
    Prada, CE
    Kipps, TJ
    BLOOD, 2004, 104 (11) : 690A - 690A
  • [2] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED OR REFRACTORY HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Pileckyte, R.
    Jurgutis, M.
    Valceckiene, V.
    Stoskus, M.
    Gineikiene, E.
    Sejoniene, J.
    Degulys, A.
    Jakubauskas, A.
    Griskevicius, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 325 - 325
  • [3] Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
    Castro, J. E.
    James, D. F.
    Sandoval-Sus, J. D.
    Jain, S.
    Bole, J.
    Rassenti, L.
    Kipps, T. J.
    LEUKEMIA, 2009, 23 (10) : 1779 - 1789
  • [4] Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
    J E Castro
    D F James
    J D Sandoval-Sus
    S Jain
    J Bole
    L Rassenti
    T J Kipps
    Leukemia, 2009, 23 : 1779 - 1789
  • [5] Combined Rituximab and high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.
    Bole, J
    Yan, L
    Tsukada, N
    Kipps, TJ
    BLOOD, 2002, 100 (11) : 802A - 802A
  • [6] Erratum: Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
    J E Castro
    D F James
    J D Sandoval-Sus
    S Jain
    J Bole
    L Rassenti
    T J Kipps
    Leukemia, 2009, 23 : 2326 - 2326
  • [7] A Phase Ib/II Study of Combined Obinutuzumab and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Castro, Januario E.
    Choi, Michael Y.
    Amaya-Chanaga, Carlos I.
    Nguyen, Natalie
    Ale-Ali, Amine
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [8] Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
    Pileckyte, Regina
    Valceckiene, Vilma
    Stoskus, Mindaugas
    Matuzeviciene, Reda
    Sejoniene, Jurgita
    Zvirblis, Tadas
    Griskevicius, Laimonas
    MEDICINA-LITHUANIA, 2019, 55 (11):
  • [9] A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Castro, Januario E.
    Choi, Michael Y.
    Amaya-Chanaga, Carlos I.
    Nguyen, Natalie
    MacCarthy, Colin
    Kipps, Thomas J.
    BLOOD, 2016, 128 (22)
  • [10] A phase Ib/II study of obinutuzumab and high-dose methylprednisolone (HDMP) for therapy of patients with chronic lymphocytic leukemia (CLL)
    Castro, Januario
    Choi, Michael Y.
    Amaya-Chanaga, Carlos I.
    Nguyen, Natalie
    Ale-Ali, Amine
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2015, 56 : 18 - 19
12345